MoonLake (MLTX) Stock Jumps After Sonelokimab Shows Positive 52-Week Data in Hidradenitis Suppurativa Trial

MoonLake Immunotherapeutics (MLTX) shares surged on June 22, 2026, following the announcement of positive 52-week data from its Phase 2 MIRA trial of sonelokimab. The drug, targeting moderate-to-severe hidradenitis suppurativa (HS), demonstrated sustained efficacy and a consistent safety profile, reinforcing its potential as a leading treatment. The 120mg sonelokimab dose group maintained high response rates at week 52, with 68% of patients achieving HiSCR50 (50% reduction in abscesses and inflammatory nodules), 54% reaching HiSCR75, and 33% achieving HiSCR90. The safety profile remained consistent with no new signals observed, building on the favorable 16-week data. These results position sonelokimab as a potential best-in-class treatment for HS. MoonLake plans to advance the drug to Phase 3 trials, targeting a significant market for this chronic inflammatory skin condition.